# Investigating the functions and molecular mechanisms of DTX3L in cancer progression

## TL;DR

This paper reviews how DTX3L, an E3 ubiquitin ligase, influences cancer progression and its potential as a therapeutic target.

## Contribution

The paper systematically summarizes recent findings on DTX3L's role in cancer and its mechanisms.

## Key findings

- DTX3L regulates key cancer-related processes like cell proliferation and apoptosis.
- DTX3L's substrate selectivity makes it a promising target for cancer therapy.
- More research is needed to validate DTX3L-targeted therapies for clinical use.

## Abstract

In the field of tumor research, the process by which E3 ubiquitin ligases specifically ubiquitinate substrate proteins and promote their degradation has garnered significant attention. DTX3L, an emerging E3 ubiquitin ligase of the Deltex family, is closely associated with the development and progression of various malignant tumors. Through multiple mechanisms such as epigenetic modifications, signal pathway activation, and protein interaction networks, DTX3L precisely regulates key biological processes, including cell proliferation, cycle progression, migration, invasion, and apoptosis. This review systematically summarizes cutting-edge research findings on DTX3L across numerous malignant tumors and analyzes its regulatory mechanisms and functional manifestations in these cancers. From a clinical translation perspective, DTX3L, with its unique substrate selectivity, is becoming a promising cancer therapeutic target. However, therapeutic strategies targeting DTX3L require more in-depth and thorough validation for clinical translation. In summary, DTX3L is expected to serve as a crucial bridge connecting basic research with clinical applications, playing a significant role in cancer precision diagnosis and treatment.